PPM-18
Based on 1 Customer Validation
PPM-18 (NSC 73233) is a Vitamin K (HY-B2172) analog. PPM-18 prevents LPS-induced IκBα degradation, thereby inhibiting NF-κB activation and nuclear translocation of NF-κB. PPM-18 inhibits LPS-induced nitrite production and iNOS expression. PPM-18 inhibits HDAC6. PPM-18 induces ROS accumulation, activates AMPK, inhibits the mTORC1 and PI3K/AKT pathways, initiates Autophagy, and induces Apoptosis. PPM-18 suppresses seizures in zebrafish and mouse epilepsy models. PPM-18 prevents LPS-induced lethal toxicity and delayed hypotension. PPM-18 exhibits anticancer activity against leukemia and bladder cancer. PPM-18 can be used in research related to septic shock, bladder cancer and atherosclerosis.
For research use only. We do not sell to patients.
- Purity: 99.17%
- CAS No.: 65240-86-0
- Formula: C17H11NO3
- Molecular Weight:277.27
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
All AMPK Isoforms
More
Biological Activity
|
iNOS |
HDAC6 |
mTORC1 |
PPM-18 (0.1-10 µM; 24 h) inhibits lipopolysaccharide (LPS)-induced nitric oxide production (measured by nitrite content) in rat alveolar macrophages in a dose-dependent manner, with the maximal inhibitory effect observed at 10 µM[1].
PPM-18 (3-10 µM; 24 h) inhibits lipopolysaccharide (LPS)-induced iNOS protein expression in rat alveolar macrophages[1].
PPM-18 (3-10 µM; preincubated prior to 6 h LPS stimulation) inhibits lipopolysaccharide (LPS)-induced accumulation of iNOS mRNA in rat alveolar macrophages[1].
PPM-18 (10 µM; 60 min preincubation prior to 30 min LPS stimulation) inhibits lipopolysaccharide (LPS)-induced nuclear translocation of NF-κB p65 in rat alveolar macrophages[1].
PPM-18 (10-30 µM; 60 min preincubation prior to 30 min LPS stimulation for whole-cell assays) inhibits lipopolysaccharide (LPS)-induced NF-κB-DNA binding activity in intact rat alveolar macrophages, but does not directly interfere with NF-κB-DNA binding in isolated nuclear extracts[1].
PPM-18 (10 µM; 24 h) inhibits LPS-induced TNF-α release from rat alveolar macrophages[1].
PPM-18 (5-20 μM; 6-24 h) reduces the viability of bladder cancer T24 and EJ cells in a dose- and time-dependent manner[2].
PPM-18 (5-15 μM; 24 h) induces autophagy in bladder cancer T24 and EJ cells in a dose-dependent manner, and this effect can be detected by decreased p62 expression and increased LC3B II expression[2].
PPM-18 (10 μM; 1 h) completely inhibits shear-induced nuclear translocation of NF-κB subunits p50 and p65[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:rat alveolar macrophages
-
Concentration:3-10 µM
-
Incubation Time:24 h
-
Result:Inhibited LPS-induced iNOS protein expression, with 10 µM showing a greater inhibitory effect than 3 µM.
-
Cell Line:rat alveolar macrophages
-
Concentration:3-10 µM
-
Incubation Time:preincubated prior to 6 h LPS stimulation
-
Result:Inhibited LPS-induced accumulation of iNOS mRNA, with 10 µM showing near-complete inhibition and 3 µM showing partial inhibition.
-
Cell Line:rat alveolar macrophages
-
Concentration:10 µM
-
Incubation Time:60 min preincubation prior to 30 min LPS stimulation
-
Result:Significantly inhibited LPS-induced nuclear accumulation of NF-κB p65.
-
Cell Line:rat alveolar macrophages
-
Concentration:10 µM
-
Incubation Time:24 h
-
Result:Inhibited LPS-induced TNF-α increase, reducing TNF-α levels from 2711 pg/mL (LPS alone) to 260 pg/mL (P < 0.001).
-
Cell Line:human bladder cancer T24 and EJ cells
-
Concentration:5-20 μM (dose-response); 15 μM (time-response)
-
Incubation Time:24 h (dose-response); 6-24 h (time-response)
-
Result:Reduced T24 and EJ cell viability in a dose- and time-dependent manner.
Significantly decreased viability at 10, 15, 20 μM (***p < 0.001 vs. control) for both cell lines at 24 h.
Reduced viability significantly at 18 and 24 h (***p < 0.001 vs. control) for both lines with 15 μM treatment.
PPM-18 (15 mg/kg; i.v.; single dose; 20 minutes prior to LPS) prevents delayed hypotension and inhibits LPS-induced increases in total plasma nitrite in a rat model of endotoxic shock[1].
PPM-18 (10 mg/kg; intratumoral injection; daily; 30 days) inhibits bladder cancer xenograft growth, increases tumor cell autophagy and apoptosis via ROS and AMPK pathways, improves mouse survival to 85.7%, and exhibits low in vivo toxicity[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/c (20-25 g)[1]
-
Dosage:5 mg/kg; 15 mg/kg
-
Administration:i.p.; single dose; 2 hours prior to LPS
-
Result:Reduced LPS-induced mortality to 55% at 5 mg/kg.
Reduced LPS-induced mortality to 30% at 15 mg/kg.
Conferred 70% protection at 15 mg/kg.
-
Animal Model:Wistar (male, 300-350 g)[1]
-
Dosage:15 mg/kg
-
Administration:i.v.; single dose; 20 minutes prior to LPS
-
Result:Maintained mean arterial pressure at 100 mmHg at 3 hours post-LPS, a significant difference compared to LPS-only controls (P < 0.001).
Reduced total plasma nitrite levels to 10.5 μM at 360 minutes post-LPS, similar to sham-operated rats.
-
Animal Model:BALB/c nude (female, 4-5 weeks old, subcutaneous xenograft of human EJ bladder cancer cells)[2]
-
Dosage:10 mg/kg
-
Administration:intratumoral injection; daily; 30 days
-
Result:Significantly reduced tumor volume compared to controls.
Increased mouse survival rate to 85.7% vs. 14.3% in controls.
Increased tumor tissue expression of cleaved caspase-3, LC3B, and phospho-AMPK.
Reduced tumor tissue Ki67 expression.
Increased tumor cell apoptosis measured by TUNEL staining.
Increased tumor ROS production measured by DHE staining.
Caused no significant change in mouse body weight.
Showed no major organ toxicity observed via H&E staining of heart, liver, spleen, lung, and kidney.
Chemical Information
-
CAS No. 65240-86-0
-
Appearance Solid
-
Molecular Weight 277.27
-
Formula C17H11NO3
-
Color Orange to red
-
SMILES
O=C(NC(C1=O)=CC(C2=C1C=CC=C2)=O)C3=CC=CC=C3
-
Synonyms
NSC 73233
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
[1]. Yu SM, et al. Inhibition of nitric oxide synthase expression by PPM-18, a novel anti-inflammatory agent, in vitro and in vivo. Biochem J. 1997;328 ( Pt 2)(Pt 2):363-369. [Content Brief]
[2]. Lu H, et al. PPM-18, an Analog of Vitamin K, Induces Autophagy and Apoptosis in Bladder Cancer Cells Through ROS and AMPK Signaling Pathways. Front Pharmacol. 2021;12:684915. Published 2021 Jul 9. [Content Brief]
[3]. Davis ME, et al. Shear stress regulates endothelial nitric-oxide synthase promoter activity through nuclear factor kappaB binding. J Biol Chem. 2004;279(1):163-168. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)